Dr Mark Eccleston CEO of ValiRx plc and Director of Inaphaea BioLabs is delighted to confirm the execution of an evaluation and commercial use agreement with Spanish contract research organisation Xenopat.

The deal will see Inaphaea provide its patient-derived cells for evaluation and commercial use in Xenopat’s in vivo Xenograft platform.  The contract provides access to Inaphaea’s 470+ PDCs which can be added at any time. 

Read more about the announcement here.